Oxurion NV Logo

Oxurion NV

0G99.L

(0.0)
Stock Price

0,00 EUR

-235.4% ROA

632.08% ROE

-0.01x PER

Market Cap.

1.744.730,00 EUR

-8.88% DER

0% Yield

-5402.72% NPM

Oxurion NV Stock Analysis

Oxurion NV Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oxurion NV Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Oxurion NV Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oxurion NV Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Oxurion NV Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oxurion NV Revenue
Year Revenue Growth
2012 75.105.000
2013 112.781.000 33.41%
2014 13.776.000 -718.68%
2015 11.198.000 -23.02%
2016 7.104.000 -57.63%
2017 5.810.000 -22.27%
2018 5.320.000 -9.21%
2019 3.946.000 -34.82%
2020 2.077.999 -89.89%
2021 1.128.000 -84.22%
2022 595.000 -89.58%
2023 360.000 -65.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oxurion NV Research and Development Expenses
Year Research and Development Expenses Growth
2012 20.053.000
2013 35.088.000 42.85%
2014 23.857.000 -47.08%
2015 22.956.000 -3.92%
2016 24.712.000 7.11%
2017 24.009.000 -2.93%
2018 29.596.000 18.88%
2019 26.313.000 -12.48%
2020 22.542.000 -16.73%
2021 20.780.000 -8.48%
2022 15.989.000 -29.96%
2023 11.276.000 -41.8%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oxurion NV General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 9.685.000
2013 11.579.000 16.36%
2014 9.520.000 -21.63%
2015 7.945.000 -19.82%
2016 6.523.000 -21.8%
2017 6.226.000 -4.77%
2018 6.349.000 1.94%
2019 6.324.000 -0.4%
2020 5.489.000 -15.21%
2021 7.150.000 23.23%
2022 5.980.000 -19.57%
2023 4.532.000 -31.95%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oxurion NV EBITDA
Year EBITDA Growth
2012 29.771.000
2013 33.174.999 10.26%
2014 -44.584.000 174.41%
2015 -30.928.000 -44.15%
2016 -26.565.000 -16.42%
2017 -26.942.000 1.4%
2018 -36.907.000 27%
2019 -35.123.000 -5.08%
2020 -28.301.000 -24.11%
2021 -27.291.000 -3.7%
2022 -21.883.000 -24.71%
2023 -14.060.000 -55.64%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oxurion NV Gross Profit
Year Gross Profit Growth
2012 71.960.000
2013 106.397.000 32.37%
2014 9.176.000 -1059.51%
2015 7.968.000 -15.16%
2016 224.000 -3457.14%
2017 3.231.000 93.07%
2018 1.965.000 -64.43%
2019 1.687.000 -16.48%
2020 1.527.999 -10.41%
2021 516.000 -196.12%
2022 82.000 -529.27%
2023 196.000 58.16%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oxurion NV Net Profit
Year Net Profit Growth
2012 30.415.000
2013 26.401.000 -15.2%
2014 -51.115.000 151.65%
2015 -37.884.000 -34.93%
2016 -60.314.000 37.19%
2017 22.788.000 364.67%
2018 -38.474.000 159.23%
2019 -51.827.000 25.76%
2020 -28.012.000 -85.02%
2021 -29.158.000 3.93%
2022 -31.685.000 7.98%
2023 -21.246.000 -49.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oxurion NV Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 1
2013 1 0%
2014 -1 100%
2015 -1 0%
2016 -2 0%
2017 1 0%
2018 -1 100%
2019 -1 0%
2020 -1 0%
2021 -1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oxurion NV Free Cashflow
Year Free Cashflow Growth
2012 25.921.000
2013 23.555.000 -10.04%
2014 -47.150.000 149.96%
2015 -28.147.000 -67.51%
2016 -20.881.000 -34.8%
2017 26.049.000 180.16%
2018 -31.311.000 183.19%
2019 -31.572.000 0.83%
2020 -27.198.000 -16.08%
2021 -27.010.000 -0.7%
2022 -19.438.000 -38.95%
2023 -3.452.000 -463.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oxurion NV Operating Cashflow
Year Operating Cashflow Growth
2012 27.789.000
2013 25.710.000 -8.09%
2014 -46.579.000 155.2%
2015 -27.793.000 -67.59%
2016 -20.309.000 -36.85%
2017 26.295.000 177.24%
2018 -31.116.000 184.51%
2019 -31.439.000 1.03%
2020 -27.079.000 -16.1%
2021 -26.978.000 -0.37%
2022 -19.379.000 -39.21%
2023 -3.451.500 -461.47%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oxurion NV Capital Expenditure
Year Capital Expenditure Growth
2012 1.868.000
2013 2.155.000 13.32%
2014 571.000 -277.41%
2015 354.000 -61.3%
2016 572.000 38.11%
2017 246.000 -132.52%
2018 195.000 -26.15%
2019 133.000 -46.62%
2020 119.000 -11.76%
2021 32.000 -271.88%
2022 59.000 45.76%
2023 500 -11700%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oxurion NV Equity
Year Equity Growth
2012 227.966.000
2013 258.772.000 11.9%
2014 208.012.000 -24.4%
2015 170.015.000 -22.35%
2016 109.858.999 -54.76%
2017 133.357.000 17.62%
2018 105.310.000 -26.63%
2019 53.306.000 -97.56%
2020 25.048.000 -112.82%
2021 -1.108.000 2360.65%
2022 -4.583.000 75.82%
2023 -8.623.000 46.85%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oxurion NV Assets
Year Assets Growth
2012 239.171.000
2013 271.154.000 11.8%
2014 220.714.000 -22.85%
2015 178.946.000 -23.34%
2016 121.636.000 -47.12%
2017 150.437.000 19.14%
2018 114.864.000 -30.97%
2019 65.030.000 -76.63%
2020 34.284.000 -89.68%
2021 18.876.000 -81.63%
2022 11.993.000 -57.39%
2023 11.820.000 -1.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oxurion NV Liabilities
Year Liabilities Growth
2012 11.205.000
2013 12.382.000 9.51%
2014 12.702.000 2.52%
2015 8.931.000 -42.22%
2016 11.777.000 24.17%
2017 17.080.000 31.05%
2018 9.554.000 -78.77%
2019 11.724.000 18.51%
2020 9.236.000 -26.94%
2021 19.984.000 53.78%
2022 16.576.000 -20.56%
2023 20.443.000 18.92%

Oxurion NV Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.05
Price to Earning Ratio
-0.01x
Price To Sales Ratio
3.39x
POCF Ratio
-0.02
PFCF Ratio
-0.15
Price to Book Ratio
-0.02
EV to Sales
-0.85
EV Over EBITDA
0.03
EV to Operating CashFlow
0.04
EV to FreeCashFlow
0.04
Earnings Yield
-130.96
FreeCashFlow Yield
-6.73
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.14
Graham NetNet
-0.03

Income Statement Metrics

Net Income per Share
-0.05
Income Quality
0.42
ROE
4.21
Return On Assets
-3.53
Return On Capital Employed
3.62
Net Income per EBT
1
EBT Per Ebit
1.69
Ebit per Revenue
-32.01
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
9.24
Research & Developement to Revenue
23.32
Stock Based Compensation to Revenue
1.28
Gross Profit Margin
-0.23
Operating Profit Margin
-32.01
Pretax Profit Margin
-54.01
Net Profit Margin
-54.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0
Capex to Revenue
-0.02
Capex to Depreciation
-0.03
Return on Invested Capital
1.99
Return on Tangible Assets
-2.35
Days Sales Outstanding
3041.19
Days Payables Outstanding
5414.03
Days of Inventory on Hand
0
Receivables Turnover
0.12
Payables Turnover
0.07
Inventory Turnover
437000
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,02
Tangible Book Value per Share
-0.02
Shareholders Equity per Share
-0.02
Interest Debt per Share
0
Debt to Equity
-0.09
Debt to Assets
0.06
Net Debt to EBITDA
0.14
Current Ratio
0.4
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-0.09
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
1
Debt to Market Cap
0.44

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oxurion NV Dividends
Year Dividends Growth
2022 0

Oxurion NV Profile

About Oxurion NV

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

CEO
Mr. Pascal Ghoson
Employee
20
Address
Gaston Geenslaan 1
Leuven, 3001

Oxurion NV Executives & BODs

Oxurion NV Executives & BODs
# Name Age
1 Dr. Andy De Deene M.B.A., M.D.
Chief Development Officer
70
2 Mr. Pascal Ghoson
Chief Executive Officer, Chief Financial Officer & Executive Director
70
3 Philippe Barbeaux Ph.D.
Chief Scientific Officer
70

Oxurion NV Competitors